N/A
Manufactured by Stemline Therapeutics, Inc.
14,750 FDA adverse event reports analyzed
Last updated: 2026-04-15
ELACESTRANT is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Stemline Therapeutics, Inc.. The most commonly reported adverse reactions for ELACESTRANT include NAUSEA, FATIGUE, DISEASE PROGRESSION, VOMITING, DIARRHOEA. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for ELACESTRANT.
Out of 7,013 classified reports for ELACESTRANT:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 14,750 FDA FAERS reports that mention ELACESTRANT. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include NAUSEA, FATIGUE, DISEASE PROGRESSION, VOMITING, DIARRHOEA, DEATH. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Stemline Therapeutics, Inc. in connection with ELACESTRANT. Always verify the specific product and NDC with your pharmacist.